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abstract
Keywords:

This session, “Emerging Drug Problems in Asia,” focused on emerging drug problems in

Emerging drug use

Asia. Dr Juana Tomás-Rosselló discussed “East and Southeast Asia: Emerging drug prob-

Ketamine

lems and response” and Dr Wei J. Chen discussed “Ketamine use among regular tobacco

Methamphetamine

and alcohol users as revealed by respondent driven sampling in Taipei: Prevalence, expectancy, and users’ risky decision making.”
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. All rights reserved.

1.

Introduction

The nations of Asia often share common borders, waterways,
highways, and population migration patterns. Although these
connections bring many strengths to the region, they may also
serve as channels for illicit drug trafficking and use.

2.

Presentations

Dr Juana Tomás-Rosselló, South East Asia regional coordinator
for the United Nations Office on Drugs and Crime (UNODC)
Treatnet program, provided an overview of the UNODC
surveillance system [1]. Although opiate use appears to have
stabilized throughout Asia, there have been increases in methamphetamine use and the use of new psychoactive substances
(e.g., ketamine, synthetic cannabinoids, and kratom). There
continues to be a high prevalence of human immunodeficiency
virus (HIV) among injection drug users throughout Asia.
Although trafficking, drug seizure, and use patterns may
have changed, Dr Tomás-Rosselló noted that approaches to
treatment remain heavily reliant on compulsory centers for
drug users. These centers provide little access to evidencebased drug treatment or HIV care. She highlighted the need
to introduce more community-based prevention and treatment strategies. Malaysia’s Cure & Care and UNODC’s Treatnet

were offered as two examples of community-level treatment
implementation.
Taiwan’s emerging ketamine problem was next discussed
by Dr Wei Chen of the National Taiwan University, Taipei City,
Taiwan. Users of ketamine are young and are often engaged in
the dance club scene. Respondent-driven surveys have identified linkages between the high use of alcohol and tobacco and
the use of ketamine. Although there appears to be relatively
low levels of ketamine dependence, there are both significant
psychiatric and medical complications directly related to ketamine use (e.g., dissociative psychosis and cystitis). Developing a profile of those at risk for ketamine use and protocols
for managing the acute effects of ketamine are a necessary
first approach to this emerging epidemic. Further research is
needed to determine the long-term risks of ketamine use and
treatment approaches for those who become chronic ketamine
users. Details of this presentation can be found in the article by
Chen et al [2] included in this special issue.

3.

Discussion

Discussion of these two presentations focused on the use of
regional data to inform local approaches. It was acknowledged
that UNODC can only compile trafficking and drug use data
from nationally and internationally collected surveys; thus,
countries with limited data collection systems may under-
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report the scope of drug use. Although ketamine use is seen in
several other Asian countries, it is not clear if the high prevalence of use in Taiwan is unique to that setting or an early
indicator of what may be seen throughout the region. Adapting evidence-based approaches to prevention and treatment
to the local political and cultural setting will be key in
addressing new and existing drug problems in Asia.
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